These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
722 related articles for article (PubMed ID: 34935899)
1. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway. Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899 [TBL] [Abstract][Full Text] [Related]
2. Protective effect of hsa-miR-570-3p targeting CD274 on triple negative breast cancer by blocking PI3K/AKT/mTOR signaling pathway. Wang LL; Huang WW; Huang J; Huang RF; Li NN; Hong Y; Chen ML; Wu F; Liu J Kaohsiung J Med Sci; 2020 Aug; 36(8):581-591. PubMed ID: 32311203 [TBL] [Abstract][Full Text] [Related]
3. Hsa_circ_0000199 facilitates chemo-tolerance of triple-negative breast cancer by interfering with miR-206/613-led PI3K/Akt/mTOR signaling. Li H; Xu W; Xia Z; Liu W; Pan G; Ding J; Li J; Wang J; Xie X; Jiang D Aging (Albany NY); 2021 Jan; 13(3):4522-4551. PubMed ID: 33495420 [TBL] [Abstract][Full Text] [Related]
4. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis. Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937 [TBL] [Abstract][Full Text] [Related]
5. ROR2 promotes invasion and chemoresistance of triple-negative breast cancer cells by activating PI3K/AKT/mTOR signaling. DA X; Ge H; Shi J; Zhu C; Wang G; Fang Y; Xu J Oncol Res; 2024; 32(7):1209-1219. PubMed ID: 38948021 [TBL] [Abstract][Full Text] [Related]
6. Dihydrotestosterone Induces Chemo-Resistance of Triple-Negative Breast MDA-MB-231 Cancer Cells Towards Doxorubicin Independent of ABCG2 and miR-328-3p. Al-Momany B; Hammad H; Ahram M Curr Mol Pharmacol; 2021; 14(5):860-870. PubMed ID: 34061013 [TBL] [Abstract][Full Text] [Related]
7. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655 [TBL] [Abstract][Full Text] [Related]
8. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A. Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639 [TBL] [Abstract][Full Text] [Related]
9. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway. Wu C; Qiu S; Liu P; Ge Y; Gao X J Ethnopharmacol; 2018 Jan; 211():89-100. PubMed ID: 28962890 [TBL] [Abstract][Full Text] [Related]
10. [Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer]. Ma T; Zhang J; Wu J; Tang J Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 May; 39(5):488-95. PubMed ID: 24921394 [TBL] [Abstract][Full Text] [Related]
11. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2. Gao Z; Shi M; Wang Y; Chen J; Ou Y Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851 [TBL] [Abstract][Full Text] [Related]
12. Silence of α1-Antitrypsin Inhibits Migration and Proliferation of Triple Negative Breast Cancer Cells. Zhao Z; Ma J; Mao Y; Dong L; Li S; Zhang Y Med Sci Monit; 2018 Sep; 24():6851-6860. PubMed ID: 30260937 [TBL] [Abstract][Full Text] [Related]
13. Formononetin relieves the facilitating effect of lncRNA AFAP1-AS1-miR-195/miR-545 axis on progression and chemo-resistance of triple-negative breast cancer. Wu J; Xu W; Ma L; Sheng J; Ye M; Chen H; Zhang Y; Wang B; Liao M; Meng T; Zhou Y; Chen H Aging (Albany NY); 2021 Jul; 13(14):18191-18222. PubMed ID: 34289449 [TBL] [Abstract][Full Text] [Related]
14. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation. Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652 [TBL] [Abstract][Full Text] [Related]
15. Relevance and mechanism of STAT3/miR-221-3p/Fascin-1 axis in EGFR TKI resistance of triple-negative breast cancer. Jin LL; Lu HJ; Shao JK; Wang Y; Lu SP; Huang BF; Hu GN; Jin HC; Wang CQ Mol Cell Biochem; 2024 Nov; 479(11):3037-3047. PubMed ID: 38145448 [TBL] [Abstract][Full Text] [Related]
16. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway. Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829 [TBL] [Abstract][Full Text] [Related]
17. MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2. Chen H; Pan H; Qian Y; Zhou W; Liu X Mol Cancer; 2018 Jan; 17(1):4. PubMed ID: 29310680 [TBL] [Abstract][Full Text] [Related]
18. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24. Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer. Haga Y; Higashisaka K; Yang L; Sekine N; Lin Y; Tsujino H; Nagano K; Tsutsumi Y Biochem Biophys Res Commun; 2020 Dec; 533(4):672-678. PubMed ID: 33036754 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway. Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]